Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma

Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma

Original Study Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma Gregory R. Pond,1 Matthew I. Milowsky,2 Mich...

427KB Sizes 0 Downloads 64 Views

Original Study

Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma Gregory R. Pond,1 Matthew I. Milowsky,2 Michael P. Kolinsky,3 Bernhard J. Eigl,4 Andrea Necchi,5 Lauren C. Harshman,6 Giuseppe Di Lorenzo,7 Tanya B. Dorff,8 Richard J. Lee,9 Guru Sonpavde10 Abstract Chemoradiotherapy is often administered for locally advanced penile squamous cell carcinoma (PSCC), an orphan malignancy, but outcomes with this approach are unclear. This retrospective analysis of 26 patients reports outcomes with concurrent chemoradiotherapy for locally advanced and advanced PSCC. The study highlights dismal outcomes with chemoradiotherapy and suggests the need for better understanding of tumor biology and evaluation of novel systemic agents. Background: Outcomes with concurrent chemoradiotherapy for penile squamous cell carcinoma (PSCC) are unclear, and only anecdotal reports have been published. This study was a retrospective analysis of patients who received concurrent chemotherapy and radiotherapy for PSCC. Patients and Methods: Individual patientelevel data were obtained from 5 institutions for outcomes with concurrent chemoradiotherapy for PSCC. Descriptive statistics were calculated, and univariable Cox proportional hazards regression analysis was conducted to examine the prognostic effect of candidate factors on progression-free survival (PFS) and overall survival (OS). Results: A total of 26 men were evaluable. The mean age was 60.3 years. The clinical stage was  III in 9 patients (36%) and stage IV in the rest. Soft tissue and visceral metastasis were present in 35% and 20% of patients, respectively. The chemotherapy was cisplatin-based in 92.3% of patients, and the median (range) of external beam radiotherapy administered was 4900 cGy (range, 1800-7000 cGy). The median OS was 6.9 months (95% CI, 5-14), and the median PFS was 5.1 months (95% CI, 2.5-7.0). When excluding patients with M1 disease, the remaining patients (n ¼ 21) had a median OS and PFS of 10.0 months (95% CI, 5-14) and 6.0 months (95% CI, 2.0-7.0), respectively. Baseline neutrophil to lymphocyte ratio (NLR) was significantly associated with survival, and visceral metastasis showed a trend for association with OS. Conclusions: Concurrent chemoradiotherapy demonstrated poor outcomes for locally advanced PSCC. Better understanding of tumor biology and study of novel combinations of biologic agents with radiation are warranted. Clinical Genitourinary Cancer, Vol. -, No. -, --- ª 2014 Elsevier Inc. All rights reserved. Keywords: Chemoradiation, Locally advanced, Outcomes, Penile squamous cell carcinoma, Prognosis

Introduction Penile squamous cell carcinoma (PSCC) is relatively rare in the western world, but developing countries exhibit higher incidences. In the United States, 1640 new cases and 320 deaths from PSCC were expected in 2014.1 The majority of patients are diagnosed at a 1

McMaster University, Hamilton, Ontario, Canada University of North Carolina, Chapel Hill, NC 3 University of Alberta, Edmonton, Alberta, Canada 4 BC Cancer Agency, Vancouver, British Columbia, Canada 5 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy 6 Dana-Farber Cancer Institute, Boston, MA 7 University Federico II, Napoli, Italy 8 University of Southern California, CA 9 Massachusetts General Hospital Cancer Center, Boston, MA 2

1558-7673/$ - see frontmatter ª 2014 Elsevier Inc. All rights reserved. http://dx.doi.org/10.1016/j.clgc.2014.03.009

localized stage and are generally managed by single-modality therapy with surgery or radiation therapy, although selected patients may be offered concurrent chemoradiotherapy. However, PSCC can exhibit aggressive biology with locoregional lymphatic spread and subsequent distant metastasis. Patients with distant metastatic disease 10 University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, Birmingham, AL

Submitted: Jan 17, 2014; Revised: Mar 01, 2014; Accepted: Mar 11, 2014 Address for correspondence: Guru Sonpavde, MD, Associate Professor of Medicine, Division of Hematology-Oncology, UAB Comprehensive Cancer Center, 1802 6th Ave S, NP2540, Birmingham, AL 35294 E-mail contact: [email protected]

Clinical Genitourinary Cancer Month 2014

-1

Chemoradiotherapy for Penile Cancer Table 1 Continued

Table 1 Baseline Patient Characteristics

n (%)

n (%) Patient Characteristics (n ¼ 26 Unless Otherwise Noted)

Tumor Characteristics Clinical Stageb

Site Alberta

8 (30.8)

2

British Columbia

6 (23.1)

3

4 (15.4)

North Carolina

8 (30.8)

4

16 (61.5)

Dana-Farber

2 (7.7)

Unknown

Milan

2 (7.7) 60.3 (12.4)

Smoking Status Never

8 (30.8)

3 (11.5)

1

2 (7.7)

2

18 (69.2)

3 Visceral Metastases

3 (11.5) c

9 (34.6)

Current

5 (19.2)

Yes

2 (7.7)

Unknown

4 (15.4)

Unknown

6 (23.1)

No

Soft Tissue Metastases 17 (65.4)

Yes, Neonatal

0 (0.0)

Yes, Postneonatal

3 (11.5)

Unknown

6 (23.1)

ECOG Performance Status 0

1 (3.8)

1

5 (19.2)

2 3 Unknown

3 (11.5) 3 (11.5) 14 (53.8)

Mean (SD)

12.8 (1.5)

Neutrophils (n ¼ 25) Mean (SD)

7.7 (3.9) 1.5 (0.5) 4.4 (1.5-16.2)

Albumin (n ¼ 20) Mean (SD)

6 (23.1)

Pathology Papillary

1 (3.9)

Verrucous

1 (3.9)

Sarcomatoid

1 (3.9)

Not Specified

23 (88.5)

Lymphovascular Invasion Yes Unknown

13 (50.0) 4 (15.4)

Chemotherapy Regimen No Platinum

24 (92.3) 2 (7.7)

Specific Chemotherapy Regimen

Neutrophils/Lymphocytes Ratio (n ¼ 25) Median (range)

7 (26.9)

Unknown

Cisplatin-Based

Lymphocytes (n ¼ 25) Mean (SD)

Yes

Treatment Characteristics

Hemoglobin

3.6 (0.6)

5-FU and Cisplatin

10 (38.5)

Cisplatin Only

14 (53.8)

5-FU Only

1 (3.9)

Bleomycin

1 (3.9)

External Beam Radiation Dose <40 Gy

4 (15.4)

12 (46.2)

40-60 Gy

16 (61.5)

Black

2 (7.7)

>60 Gy

5 (19.2)

Asian

4 (15.4)

Unknown

1 (3.9)

Hispanic/Latin American

1 (3.8)

Unknown

7 (26.9)

Race White

Family History of PSCC None

26 (100.0)

History of Precancerous Lesion n (%)

Outcomes Overall Survival (mo) n (%) Censored

8 (30.8)

Median (95% CI)

6.9 (5, 14)

1-year (95% CI) 2 (7.7)a

HIV Positive

-

Grade

Past

Circumcision

2

1 (3.8)

0

Age Mean (SD)

5 (19.2)

32.6 (14.2, 52.6)

Progression-Free Survival (mo) n (%) Censored

7 (26.9)

Negative

17 (65.4)

Median (95% CI)

5.1 (2.5, 7.0)

Unknown

9 (34.6)

1-year (95% CI)

18.7 (5.9, 36.9)

Clinical Genitourinary Cancer Month 2014

Gregory R. Pond et al Table 1 Continued n (%) Outcomes (Excluding Patients With Metastases) Overall Survival (mo) n (%) Censored

6 (28.6)

Median (95% CI)

10.0 (5, 14)

1-year (95% CI)

36.9 (16.0, 58.1)

Progression-Free Survival (mo) n (%) Censored

5 (23.8)

Median (95% CI)

6.0 (2.0, 7.0)

1-year (95% CI)

20.5 (6.4, 40.1)

Abbreviations: CI ¼ confidence interval; ECOG ¼ Eastern Cooperative Oncology Group; 5-FU ¼ 5-fluorouracil; mo ¼ month; PSCC ¼ penile squamous cell carcinoma; SD ¼ standard deviation. a One patient had previous balanitis xerotica obliterans; one had an undefined precancerous lesion. b American Joint Committee on Cancer 7th edition: stage 1, T1aN0M0; stage II, T1b-T3N0M0; stage III, T1-T3N1-N2M0; stage IV, any T4, any N3, or M1; T1a, tumor invades subepithelial connective tissue without lymphovascular invasion (LVI) and is not high grade 3-4; T1b, tumor invades subepithelial connective tissue with LVI or is grade 3-4; T2, tumor invades corpus spongiosum or cavernosum; T3, tumor invades urethra; T4, tumor invades other adjacent structures; N1, mobile unilateral inguinal lymph node; N2, mobile multiple or bilateral inguinal lymph nodes; N3, palpable fixed inguinal nodal mass or pelvic lymphadenopathy; M1, distant metastasis. Among 16 patients with stage IV disease, 5 had M1 disease and 11 had T4 disease, N3 disease, or both. c These include bone, lung, and liver disease.

are generally treated with systemic cisplatin-based combination chemotherapy.2-15 In the spectrum between local therapy alone and systemic therapy alone, multimodality therapy plays a major role. In patients with locally advanced or locoregional but operable disease, neoadjuvant cisplatin-based combination chemotherapy followed by surgery is offered.4,8,16,17 Patients with high-risk disease after initial surgery have been considered for adjuvant chemotherapy, radiotherapy, or both. Selected patients with inoperable locally advanced or locoregional disease with bulky or fixed lymphadenopathy (with or without prior surgery) are considered appropriate for a concurrent chemoradiotherapy approach, although high disease burden may lead to the institution of systemic chemotherapy alone. However, no prospective studies have been conducted to investigate outcomes with concurrent chemoradiotherapy for locoregionally advanced disease, and only anecdotal reports exist.18,19 Hence, this study was a retrospective analysis of patients with PSCC receiving concurrent chemoradiotherapy for unresectable locoregionally advanced or advanced disease to examine clinical outcomes and potential prognostic factors.

Patients and Methods Patient Population This study identified consecutive patients with PSCC who were treated between the years 2000 and 2012 at referral medical centers in North America and Europe. Eligibility required patients who had received concurrent systemic therapy with external beam radiotherapy without subsequent surgery for localized, locoregionally advanced, or metastatic disease. However, patients may have undergone previous surgery before recurrence and presentation with locoregional or advanced disease. Patients who received perioperative chemoradiotherapy were excluded. The following patient and disease characteristics at baseline were requested: Eastern

Cooperative Oncology Group performance status, American Joint Committee on Cancer 7th edition clinical stage, sites of metastases (soft tissue vs. visceral), hemoglobin, race, smoking status, circumcision status, peripheral blood neutrophil count, peripheral blood lymphocyte count, albumin, family history of penile cancer, history of precancerous lesion, HIV status, lymphovascular invasion, histologic subtype, systemic therapy regimen, and the duration to tumor progression and death from the initiation of chemoradiotherapy. The study was conducted after approval by the Institutional Review Board at the University of Alabama, Birmingham (UAB) and other participating institutions.

Statistical Methods Individual patientelevel data were combined, and patient, disease, and outcome characteristics were summarized using descriptive statistics. Durations to event outcomes were calculated using the Kaplan-Meier method. Neutrophil and lymphocyte count were assessed individually, as well as using the neutrophil/lymphocyte ratio. Dichotomization of selected categorical or ordinal variables and application of a logarithmic transformation for non-normal continuous variables were applied for statistical purposes. Univariate Cox proportional hazards regression analysis was conducted to examine the prognostic effect of the aforementioned candidate factors on overall survival (OS) and progression-free survival (PFS). Given the small sample size and limited statistical power available, it was decided a priori not to perform multivariate statistical modeling. All tests were 2-sided, and a value of P  .05 was considered statistically significant.

Results Patient Characteristics Patient data for 26 patients treated with chemoradiotherapy were captured from 5 institutions (Table 1): the University of North Carolina (Chapel Hill, NC) (n ¼ 8); the University of Alberta (Edmonton, Alberta, Canada) (n ¼ 8); the British Columbia Cancer Agency (Vancouver, British Columbia, Canada) (n ¼ 6); Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy) (n ¼ 2); and the Dana-Farber Cancer Institute (Boston, MA) (n ¼ 2). All patients had squamous cell carcinoma, although the histologic subtype was not available for most patients. The mean age of these patients was 60.3 years; 16 (61.5%) had clinical stage IV disease; and 5 patients overall had M1 disease (19.2%). Soft tissue and visceral disease were present in 26.9% and 7.7% of patients, respectively. The majority of patients (92.3%) received cisplatin-based regimens. The median dose of external beam radiotherapy administered was 4900 cGy (range, 1800-7000 cGy). The radiotherapy fields were variable between patients and institutions. After chemoradiotherapy, none of the patients underwent surgical excision.

Clinical Outcomes The 1-year OS was 32.6% (95% CI, 14.2%-52.6%), and PFS was 18.7% (95% CI, 5.9%-36.9%) (Table 1; Fig. 1A, B). When excluding patients with M1 disease, the remaining patients (n ¼ 21) exhibited 1-year OS and PFS of 36.9% (95% CI, 16.0%58.1%) and 20.5% (95% CI, 6.4%-40.1%), respectively (Table 1; Fig. 2A, B). Regarding staging, 5, 4, and 16 patients had stage II,

Clinical Genitourinary Cancer Month 2014

-3

Chemoradiotherapy for Penile Cancer Figure 1 Survival Analysis. A, Overall Survival. B, ProgressionFree Survival

III, and IV disease, with 1-year OS of 40.0% (95% CI, 5.2%75.3%), 37.5% (1.1%-80.8%), and 22.4% (4.1%-49.8%), respectively; the median OS was 10 (6-16), 5 (2.5-14), and 6.9 (3-10) months, respectively. The 6-month PFS was 20.0% (0.8%-58.2%), 0%, and 39.0% (15.1%-62.5%), respectively; the median PFS was 6 (2-7), 2.25 (1-not reached), and 5.1 (2-8) months, respectively. Only 2 patients attained durable PFS and OS > 2 years.

Univariable Analyses

4

-

On univariable analyses, baseline neutrophil to lymphocyte ratio (NLR) was the only variable that attained statistical significance as a prognostic factor for OS (hazard ratio [HR] ¼ 2.84; 95% CI, 1.157.02; P ¼ .023) (Table 2). NLR also showed a trend for association with PFS (HR ¼ 1.89 [0.84-4.21]; P ¼ .12). A trend for an unfavorable effect of visceral disease on both OS (HR ¼ 3.35 [0.6916.21]; P ¼ .13) and PFS (HR ¼ 3.40 [0.70-16.52]; P ¼ .13) was observed (Table 3). Notably, the dose of radiation was associated with a 20%-30% decreased hazard of both OS and PFS for every 10-Gy increase in dose; however, neither attained statistical significance.

Clinical Genitourinary Cancer Month 2014

Figure 2 Survival Analysis for Patients With M0 Disease. A, Overall Survival for Patients With M0 Disease. B, Progression-Free Survival for Patients With M0 Disease

Discussion Guidelines, such as from the NCCN (National Comprehensive Cancer Network), and case reports have advocated or reported chemoradiotherapy as a viable approach for locally advanced PSCC despite the lack of published data on the use of this treatment modality.18-22 The present study is the first to report outcomes in a cohort of patients receiving concurrent chemotherapy and radiotherapy for locally advanced or advanced PSCC. For this study, 26 patients from 5 institutions had data available, despite a review of databases from 13 centers, which together contributed 140 patients toward the authors’ previously reported study of chemotherapy alone as first-line therapy for locally advanced or advanced PSCC.23 These data suggest that concurrent chemoradiotherapy is seldom being considered for unresectable locoregionally advanced disease. This study’s population can be characterized as having considerably advanced and bulky disease, with stage IV disease in 61.5%, M1 disease in 19.2%, and visceral metastases in 7.7% of patients, implying that therapy was administered with palliative intention in

Gregory R. Pond et al Table 2 Univariable Analyses for Overall Survival All Data Definition

n

Hazard Ratio (95% CI)

P

/Decade /unit /unit /unit /log(unit) /unit 4 versus <4 Yes versus No Yes versus No Past versus Never Current versus Never Neonatal versus No Postneonatal versus No Cisplatin versus No 2-3 versus 0-1 Yes versus No Yes versus No /10 Gy

26 26 25 25 25 20 25 20 20 22

.98 .39 .086 .24 .023 .92 .92 .13 .91 .39

20

1.00 (0.70-1.45) 0.88 (0.65-1.18) 1.13 (0.98-1.30) 0.65 (0.32-1.33) 2.84 (1.15-7.02) 0.96 (0.42-2.18) 0.95 (0.37-2.44) 3.35 (0.69-16.21) 1.06 (0.36-3.14) 1.36 (0.39-4.74) 2.57 (0.64-10.35) 0.35 (0.05-2.66)

12 22 26 25

1.63 2.08 1.20 0.72

.47 .16 .81 .32

Factor Age Hemoglobin Neutrophils Lymphocytes Neutrophils/Lymphocytes Ratio Albumin Clinical Stage Visceral Metastases Soft Tissue Metastases Smoking Status Circumcision Chemotherapy Regimen ECOG Performance Status Lymphovascular Invasion History of Precancerous Lesion Radiation Dose

(0.43-6.13) (0.75-5.71) (0.27-5.32) (0.41-1.27)

.31

Abbreviation: ECOG ¼ Eastern Cooperative Oncology Group.

a minority of patients. The median OS was quite dismal at 6.9 months, and the median PFS was 5.1 months. When excluding patients with M1 disease, who are deemed incurable, outcomes were only slightly better, with a median OS and PFS of 10.0 months and 6.0 months, respectively. Given the lack of large prospective trials, this study combined multiple datasets of patients treated at multiple major institutions around the globe. The multicenter design of this database suggests that the findings may be applicable broadly in the real world.

Almost all patients were treated between the years 2000 and 2012, suggesting similarity of supportive care. Nevertheless, the small number of patients per institution is a limitation of this study. Quality of life data were not available, and it is not possible to discern an effect on survival, given the retrospective cohort design of this study. Toxicities, dose reductions, and interruptions were not graded or captured in an interpretable systematic fashion in these off-protocol patients. Hence, this analysis did not attempt to study toxicities. It studied patients who received concurrent

Table 3 Univariable Analyses for Progression-Free Survival All Data Definition

n

Hazard Ratio (95% CI)

P

/Decade /unit /unit /unit /log(unit) /unit 4 versus <4 Yes versus No Yes versus No Past versus Never Current versus Never Neonatal versus No Postneonatal versus No 2-3 versus 0-1 Yes versus No Yes versus No /Gy

26 26 25 25 25 20 25 20 20 22

.88 .51 .40 .24 .12 .88 .26 .13 .76 .36

20

0.97 (0.68-1.40) 0.91 (0.70-1.20) 1.06 (0.93-1.20) 0.64 (0.31-1.34) 1.89 (0.84-4.21) 1.07 (0.46-2.47) 0.58 (0.23-1.49) 3.40 (0.70-16.52) 0.85 (0.29-2.46) 1.52 (0.48-4.86) 2.63 (0.70-9.84) 0.54 (0.12-2.39)

12 22 26 25

2.16 1.60 1.30 0.80

.27 .34 .72 .33

Factor Age Hemoglobin Neutrophils Lymphocytes Neutrophils/Lymphocytes Ratio Albumin Clinical Stage Visceral Metastases Soft Tissue Metastases Smoking Status Circumcision ECOG Performance Status Lymphovascular Invasion History of Precancerous Lesion Radiation Dose

(0.56-8.38) (0.61-4.19) (0.30-5.71) (0.51-1.26)

.42

Abbreviation: ECOG ¼ Eastern Cooperative Oncology Group.

Clinical Genitourinary Cancer Month 2014

-5

Chemoradiotherapy for Penile Cancer chemoradiotherapy for gross disease and excluded those receiving adjuvant or neoadjuvant chemoradiotherapy. Patients with localized PSCC who received only radiation or received adjuvant radiation with or without chemotherapy were not included, because they were considered to have lower disease burden warranting a separate study. Almost all patients received cisplatin-based chemotherapy, suggesting relative homogeneity of systemic therapy. The radiation dose varied considerably, although the median dose was a respectable 4900 cGy. This study included univariate analyses to study potential prognostic factors and examined neutrophil and lymphocyte counts as well as ratio (NLR), because these parameters appear to be prognostic in other malignancies, perhaps owing to a reflection of the inflammatory and immune state.24-32 However, high NLR was significantly associated only with poor OS and showed a trend for association with poor PFS, which may be a reflection of small sample size. Notably, in the authors’ recently reported analysis of prognostic factors in patients with advanced PSCC receiving firstline chemotherapy, NLR was significant only in univariate but not multivariate analysis.23 Additionally, visceral metastasis demonstrated a trend as a negative prognostic factor for OS and PFS. However, these patients with visceral disease were receiving chemoradiotherapy with palliative intent, and the present authors have already recently confirmed the significant negative effect of visceral disease in patients with advanced PSCC receiving first-line systemic chemotherapy.23 Other factors such as anemia, albumin, stage, grade, performance status, and lymphovascular invasion may have attained prognostic significance in a larger cohort but may be more relevant in localized small tumors undergoing curative surgery and not in patients with bulky locally advanced and advanced disease such as those included in the present study. Tumor human papillomavirus and molecular factors were unavailable, and central pathology review could not be performed. Although the 20% to 30% decreased hazard of both OS and PFS for every 10-Gy increase in radiotherapy dose may be a function of better efficacy of higher doses, this phenomenon may reflect the confounding effect of patient selection (ie, the feasibility of higher doses with curative intent to patients with better performance status or lower tumor burden).

Conclusion Despite its limitations, this retrospective study highlights the poor outcomes observed in men with locally advanced PSCC receiving concurrent chemoradiotherapy. Indeed, these outcomes appear similar to outcomes in patients with advanced disease receiving first-line systemic chemotherapy alone, which yields median OS of 6 to 11 months.2-14 Hence, the value of radiation in locally advanced unresectable disease may be questioned, although lower stages of disease (T1-T2, N0) may derive the most benefit. Most importantly, a major role exists for understanding tumor biology and for studies investigating combinations of radiation with novel biologic agents for locally advanced PSCC, such as epidermal growth factor receptor inhibitors.

Clinical Practice Points  This is the largest study (n ¼ 26) reporting outcomes with

6

-

concurrent chemoradiotherapy for locally advanced penile squamous cell carcinoma (PSCC).

Clinical Genitourinary Cancer Month 2014

 The study highlights dismal long-term outcomes with chemo-

radiotherapy for locally advanced PSCC, with median survival of only 10.0 months in patients without distant metastases (nonM1 disease).  The study suggests a major role for understanding tumor biology and for studies evaluating combinations of radiation with novel biologic agents for locally advanced disease, such as epidermal growth factor receptor inhibitors.

Disclosure The authors have stated that they have no conflicts of interest.

References 1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29. 2. Sonpavde G, Pagliaro LC, Buonerba C, Dorff TB, Lee RJ, Di Lorenzo G. Penile cancer: current therapy and future directions. Ann Oncol 2013; 24: 1179-89. 3. Di Lorenzo G, Buonerba C, Federico P, et al. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int 2012; 110: E661-6. 4. Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010; 28:3851-7. 5. Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 1988; 27:823-4. 6. Leijte JA, Kerst JM, Bais E, Antonini N, Horenblas S. Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol 2007; 52:488-94. 7. Hakenberg OW, Nippgen JB, Froehner M, Zastrow S, Wirth MP. Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int 2006; 98:1225-7. 8. Bermejo C, Busby JE, Spiess PE, Heller L, Pagliaro LC, Pettaway CA. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol 2007; 177:1335-8. 9. Dexeus FH, Logothetis CJ, Sella A, et al. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol 1991; 146:1284-7. 10. Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol 2009; 55: 546-51. 11. Trabulsi EJ, Hoffman-Censits J. Chemotherapy for penile and urethral carcinoma. Urol Clin North Am 2010; 37:467-74. 12. Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol 1992; 147:630-2. 13. Power DG, Galvin DJ, Cuffe S, et al. Cisplatin and gemcitabine in the management of metastatic penile cancer. Urol Oncol 2009; 27:187-90. 14. Gagliano RG, Blumenstein BA, Crawford ED, Stephens RL, Coltman CA Jr, Costanzi JJ. cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study. J Urol 1989; 141:66-7. 15. Nicholson S, Hall E, Harland SJ, et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/ 001). Br J Cancer 2013; 109:2554-9. 16. Salvioni RNN, Piva L, et al. Pilot study of cisplatin, 5-fluorouracil, and a taxane (TPF) for advanced squamous cell carcinoma (SCC) of the penis. J Clin Oncol 2011; 29(suppl):(abstract 4639). 17. Theodore C, Skoneczna I, Bodrogi I, et al. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC protocol 30992). Ann Oncol 2008; 19: 1304-7. 18. Eliason M, Bowen G, Bowen A, Hazard L, Samlowski W. Primary treatment of verrucous carcinoma of the penis with fluorouracil, cis-diamino-dichloro-platinum, and radiation therapy. Arch Dermatol 2009; 145:950-2. 19. Pedrick TJ, Wheeler W, Riemenschneider H. Combined modality therapy for locally advanced penile squamous cell carcinoma. Am J Clin Oncol 1993; 16: 501-5. 20. Spiess PE, Horenblas S, Pagliaro LC, et al. Current concepts in penile cancer. J Natl Compr Canc Netw 2013; 11:617-24. 21. Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol 2009; 27:221-5. 22. Clark PE, Spiess PE, Agarwal N, et al. Penile cancer: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2013; 11:594-615. 23. Pond GR, Di Lorenzo G, Necchi A, et al. Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy [published online December 12, 2013]. Urol Oncol. http://dx.doi.org/10.1016/j.urolonc.2013.10.007.

Gregory R. Pond et al 24. Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010; 16:5805-13. 25. Gondo T, Nakashima J, Ohno Y, et al. Prognostic value of neutrophil-tolymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy [published online March 23, 2012]. Urology 2012; 79:1085-91. http://dx.doi.org/10.1016/j.urology. 2011.11.070. 26. Ohno Y, Nakashima J, Ohori M, Gondo T, Hatano T, Tachibana M. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol 2012; 187:411-7. 27. Kwon HC, Kim SH, Oh SY, et al. Clinical significance of preoperative neutrophillymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer [published online March 17, 2012]. Biomarkers 2012; 17:216-22. http://dx. doi.org/10.3109/1354750X.2012.656705. 28. Sejima T, Iwamoto H, Morizane S, et al. The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand

29. 30. 31.

32.

expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma [published online December 7, 2011]. Urol Oncol 2013; 31:1343-9. http://dx.doi.org/10.1016/j.urolonc.2011.09.008. Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009; 58:15-23. Jung MR, Park YK, Jeong O, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 2011; 104:504-10. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer [published online April 17, 2013]. Crit Rev Oncol Hematol 2013; 88:218-30. http://dx.doi.org/10.1016/j.critrevonc.2013.03.010. Keizman D, Gottfried M, Ish-Shalom M, et al. Pretreatment neutrophil-tolymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist 2012; 17:1508-14.

Clinical Genitourinary Cancer Month 2014

-7